News

Gliclazide is an oral anti-diabetic (hypoglycemic) drug which is classified as a sulfonylurea and is indicated for the control of hyperglycemia in gliclazide-responsive diabetes of stable, mild, non-ketosis

Prior to joining Affymetrix, Witney worked as the president and CEO of Dionex Before joining Dionex, Witney served as executive vice president and chief commercial officer of Affymetrix,

With this extension, NTT DATA will continue to sell Datatrak eClinical and Enterprise Transfer services within the Japanese market. Moreover, Datatrak has decided to extend its product’s capabilities

Soliris (eculizumab) is indicated as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Alexion plans to launch the drug for the treatment of aHUS in the

The contract aims to refine, analyze and synthesize the active molecules derived from Health Enhancement Products’ proprietary algal extracts. The active molecules were the focus of the company’s

Patents currently granted cover Europe, the USA, Canada, Japan and India, with more patents in other countries being filed. The portable system has been developed for the treatment

With this expansion, the companies expect to develop and commercialize the HAE drug in Latin America, excluding Mexico and the Caribbean, Taiwan, Singapore and South Korea. Under their

Initially, the company plans to roll out approximately 10-12 eye care pharma products in the metro cities of India by end of July, Pharmabizz reported. Bausch & Lomb‘s

The new patent entitled, ‘Retinal Derivatives and Methods for the Use Thereof for the Treatment of Visual Disorders,’ covers methods of utilizing QLT091001 to treat diseases linked with